Lemborexant trial explores reducing neurodegeneration biomarkers like pTAU181 in adults with insomnia
Background
Alzheimer's disease (AD) pathology, characterized by amyloid plaques and tau tangles, begins decades before clinical symptoms. Interventions that can slow or prevent this early process are crucial. Insomnia is a common comorbidity and potential risk factor for neurodegeneration, with sleep disruption potentially accelerating AD-related pathology. Dual orexin receptor antagonists (DORAs), developed for insomnia, may offer neuroprotective benefits by improving sleep and potentially impacting AD-related pathways. This trial explores if improving sleep with a DORA can directly reduce neurodegeneration biomarkers.
Study Design
This randomized, placebo-controlled clinical trial involves adults with insomnia. Participants will take 10mg Lemborexant nightly for two weeks, and a matching placebo nightly for two weeks, in a likely crossover design. The primary endpoint is the reduction in blood-based phosphorylated TAU181 (pTAU181). Secondary endpoints include other blood-based biomarkers of neurodegeneration such as pTAU217, amyloid beta 40:42 ratio, Neurofilament Light Chain (NFL), and Glial Fibrillary Acidic Protein (GFAP). Participants will undergo a screening visit and overnight visits at the conclusion of each two-week study drug treatment period.
Results
The primary objective of this clinical trial is to determine if Lemborexant reduces blood-based phosphorylated TAU181 (pTAU181) in adults with insomnia when compared to placebo. This investigation seeks to establish whether improving sleep with a dual orexin receptor antagonist can directly modulate these critical indicators of Alzheimer's disease pathology. The study design involves comparing biomarker levels after two weeks of Lemborexant treatment against a two-week placebo period, with measurements taken at the conclusion of each treatment phase. Secondary objectives include assessing the impact of Lemborexant on other key blood-based biomarkers of neurodegeneration.
Specifically, the trial aims to evaluate changes in phosphorylated TAU217 (
pTAU217), the amyloid beta 40:42 ratio, Neurofilament Light Chain (NFL), and Glial Fibrillary Acidic Protein (GFAP) following Lemborexant administration.
Key Findings
- Assess if Lemborexant reduces blood-based phosphorylated TAU181 compared to placebo.
- Evaluate Lemborexant's effect on phosphorylated TAU217 levels.
- Examine Lemborexant's impact on amyloid beta 40:42 ratio.
- Determine if Lemborexant reduces Neurofilament Light Chain (NFL).
- Investigate Lemborexant's influence on Glial Fibrillary Acidic Protein (GFAP).
Why It Matters
If Lemborexant proves effective, it could offer a novel, non-amyloid-targeting strategy for early neuroprotection in individuals with insomnia, a known risk factor for Alzheimer's disease. This trial explores a direct link between sleep modulation and biomarker reduction, potentially broadening the therapeutic scope of DORAs beyond just sleep improvement. A positive outcome could lead to further research into using existing insomnia medications to mitigate neurodegeneration, offering a readily available intervention. It could also highlight the critical role of sleep quality in brain health, influencing future recommendations for managing insomnia in at-risk populations and potentially informing new therapeutic protocols.
lemborexant
insomnia
neurodegeneration
alzheimers
dora
orexin-antagonist